OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
25 apr 2007 - 07:20
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus obtains full rights to PolyActive drug delivery technology from IsoTis
Bericht
OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), the drug delivery and development company, announces today that it reached agreement with IsoTis, Inc. (NASDAQ: ISOT) to obtain additional rights to its PolyActive™ drug delivery technology, the technology used in OctoPlus’ lead product Locteron™. Locteron is a controlled release formulation of interferon alfa for the treatment of chronic hepatitis C, currently in Phase IIa studies.
Under the revised agreement, OctoPlus obtains full rights to the PolyActive technology and its intellectual property in certain strategic areas, including additional applications in orthopedics. Furthermore, the contract has financial benefits for OctoPlus as it includes an upfront license fee of € 1.25 million, which will decrease future payments on OctoPlus’ revenues using PolyActive.
Datum laatste update: 29 december 2025